Massachusetts is currently home to 3209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Boston, Massachusetts
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
OurSleepKit to Support CPAP Adherence
NCT06621511
Recruiting
The goal of this clinical trial is to learn if a couple-focused mobile health intervention will improve the use of continuous positive airway pressure (CPAP), the primary treatment option for obstructive sleep apnea (OSA). Participants include newly diagnosed patients with OSA who are candidates for CPAP treatment and their partners. The couples will received supportive information and resources on their mobile devices before CPAP begins and continuing for 6 months into CPAP treatment. Their int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Northeastern University, Boston, Massachusetts
Conditions: Obstructive Sleep Apnea, CPAP Treatment, Treatment Adherence
Register for Updates
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
02/12/2025
Locations: Massachusetts Eye & Ear, Boston, Massachusetts
Conditions: Sleep Apnea, Obstructive
Register for Updates
Virtual Health Insurance Navigation Pilot Program for Childhood Survivors (HINTII)
NCT05527392
Recruiting
The investigators are conducting a Type I hybrid effectiveness-implementation trial to assess the effectiveness of HINT-S (synchronous) compared to enhanced usual care (EUC) in promoting health insurance literacy, thus reducing worry, unmet health care needs, and financial consequences due to medical costs to improve care and long-term outcomes of childhood cancer survivors. The investigators will also compare HINT-S to HINT-A (asynchronous), a prerecorded, asynchronous version of the 5 HINT-S n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Childhood Cancer Survivors
Register for Updates
Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures
NCT04604418
Recruiting
The incidence of moderate to severe congenital heart disease (CHD) in the United States is estimated to be 6 per 1000 live-born full term infants. Recent advances in pediatric cardiology, surgery and critical care have significantly improved the survival rates of patients with CHD leading to an increase in prevalence in both children and adults. Children with CHD significant enough to require cardiac surgery frequently also undergo non-cardiac surgical procedures. Analysis of the Pediatric Healt... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/12/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Congenital Heart Disease in Children
Register for Updates
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Dana Farber Cancer Institute., Boston, Massachusetts
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Register for Updates
The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric
NCT03054831
Recruiting
Oxycodone is an oral opioid analgesic that is most commonly prescribed for the management of pain in post-operative patients at Boston Children's Hospital. Oxycodone has been widely used in adults and children to relieve post-operative pain. However, its pharmacokinetics (what it does in the body) and pharmacodynamics (how it works) have not been well established in children. Some children, because of their specific genetic make-up, may metabolize the drug more quickly and therefore may be at ri... Read More
Gender:
ALL
Ages:
Between 2 years and 8 years
Trial Updated:
02/12/2025
Locations: Boston Children Hospital, Boston, Massachusetts
Conditions: Liquid Oxycodone
Register for Updates
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
NCT02044497
Recruiting
Oxycodone is an oral opioid analgesic that is most commonly prescribed for the management of pain in post-operative patients at Boston Children's Hospital. Oxycodone has been widely used in adults and children to relieve post-operative pain. However, its pharmacokinetics (what it does in the body) and pharmacodynamics (how it works) have not been well established in children. Some children, because of their specific genetic make-up, may metabolize the drug more quickly and therefore may be at ri... Read More
Gender:
ALL
Ages:
6 years and below
Trial Updated:
02/12/2025
Locations: Boston Children Hospital, Boston, Massachusetts
Conditions: Pediatric Surgical Patient
Register for Updates
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas
NCT06709495
Recruiting
This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing Sarcoma (EWS) and Desmoplastic Small Round Cell Tumor (DSRCT), as well as multiple other kinds of sarcomas. The names of the study drugs and biological agents involved in this study are: * PEEL-224 (a type of Topoisomerase 1 inhibitor) * Vincristine (A type of vinca alkalo... Read More
Gender:
ALL
Ages:
Between 12 years and 49 years
Trial Updated:
02/11/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Register for Updates
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
NCT06202274
Recruiting
This is a non-randomized, multi-center, open-label, prospective clinical study evaluating the clinical treatment with Candela Medical Technology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Candela Institue for Excellence, Marlborough, Massachusetts
Conditions: Hair Reduction, Tattoo Removal, Wrinkle, Acne, Scars, Benign Cutaneous Vascular Lesions, Skin Conditions
Register for Updates
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750
Recruiting
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in three parts; in Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Register for Updates
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
NCT06064071
Recruiting
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/11/2025
Locations: Candela Institute of Excellence, Marlborough, Massachusetts
Conditions: Meibomian Gland Dysfunction, Dry Eye Disease
Register for Updates